FDA Panel Vote on Grail's Galleri Test: What to Watch on September 23
On September 23, 2026, FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee meets in open session to discuss, make recommendations and vote on premarket approval information for GRAIL Inc.'s Galleri test. FDA identified the subject as GRAIL's premarket approval application (PMA) for Galleri in meeting materials posted September 8. FDA meeting notice
The vote is advisory. The question for the panel is benefit versus risk for use as a screening test, judged against the PMA standard.
What is under review
Galleri is a qualitative, next-generation sequencing-based in vitro diagnostic test intended to detect cancer-specific methylation patterns. That wording comes from FDA's advisory committee calendar entry for the September 23 meeting. In plain terms, qualitative means a yes-or-no signal, sequencing means reading DNA, methylation means chemical tags on DNA, and in vitro diagnostic means a test run on a sample in a lab. FDA prepared an Executive Summary titled 'GRAIL Inc., Galleri' for the panel, dated September 23, and listed briefing materials for the Galleri multi-cancer early detection test as available for public release. FDA Executive Summary
Galleri is being reviewed under PMA, the most stringent device marketing pathway. PMA requires valid scientific evidence of safety and effectiveness for the intended use. For a multi-cancer early detection test, review centers on intended use, the screening population, the follow-up protocol after a result, and how tissue-of-origin information is handled. The panel was asked to consider PMA information, not a 510(k) argument based on being substantially equivalent to a device already sold.
GRAIL submitted the Galleri PMA to FDA on January 29, 2026. The company announced that timeline and the scheduling of the advisory meeting on August 7, 2026. GRAIL announcement FDA had designated Galleri as a Breakthrough Device in 2018, according to the same company announcement. That designation affects interaction with FDA and review prioritization. It does not decide approvability.
Staff signal and timeline
FDA staff flagged no major concerns for the Galleri test ahead of the meeting, according to reporting on the briefing documents published September 21. Reuters Staff documents frame issues for panel discussion.
The broader context here is tone. A neutral-to-positive staff tone usually puts panel debate on conditions, labeling and postmarket requirements rather than basic approvability. The vote count and the exact questions voted on will matter more than the headline.
Grail shares rose 5% after news that FDA planned a September advisory meeting to review Galleri, as reported August 7. Reuters
In my view, that early 5% move reflected scheduling certainty, not the outcome. Advisory meetings create event risk. Staff documents, panel makeup, voting questions and dissent often move expectations more than the decision to meet.
FDA advisory committees support the agency's mission of protecting and promoting public health while meeting Federal Advisory Committee Act requirements. Committees are either mandated by statute or established at the discretion of the Department of Health and Human Services. Each committee is subject to renewal at two-year intervals unless its charter states otherwise.
FDA scheduled a November 29, 2023 Molecular and Clinical Genetics Panel meeting to discuss and make recommendations on the design of multi-cancer detection (MCD) in vitro diagnostic devices. That session addressed evidentiary expectations before any product-specific PMA vote. The September 23, 2026 meeting applies that framework to a specific dossier.
The broader context here is continuity. Panelists familiar with the 2023 discussion will likely probe clinical study design, endpoints, control of bias, and the link between test result and clinical action.
CMS parallel
CMS lists the Multi-Cancer Early Detection - Real-World Evidence Program in the Medicare Population among investigational device exemption (IDE) studies that have met CMS standards for coverage. CMS identifies that program as IDE study G220255-NCT05673018. CMS IDE list IDE means permission to study an experimental device in people.
CMS also hosts a Medicare Coverage Database public-comments page for Screening for Colorectal Cancer - Blood-Based Biomarker Tests that mentions the Galleri multi-cancer early detection blood test. The mention does not establish coverage. For PMA approval, FDA evaluates safety and effectiveness. For coverage, CMS evaluates whether the test is reasonable and necessary for the Medicare population. IDE coverage for routine costs in an approved study is distinct from a national coverage determination for the test itself.
The broader context here is payment. Reimbursement sits outside FDA's job but inside how investors value the company. The mention shows overlap between single-cancer blood-test policy and multi-cancer evidence work, without promising payment.
In my view, sequencing matters. A favorable panel vote would lower risk on the PMA step without resolving coding, pricing or coverage. An IDE study meeting CMS standards supports evidence generation in Medicare beneficiaries. It does not commit CMS to pay for Galleri as a screening benefit. Three tracks stay separate: panel recommendation, FDA action on the PMA, and CMS evidence requirements.
In my view, the papers to weight are the Executive Summary, the voting questions and any FDA-proposed conditions. Staff flagging no major concerns reduces tail risk around data integrity or manufacturing. It leaves open the core screening questions: performance across cancer types and stages, false-positive burden and diagnostic workup, false-negative reassurance, and durability of benefit in an intended-use population. Those are the areas where panel discussion can shift FDA's view on labeling limits and postmarket study design, even with a positive vote.
